Protective effect of angiotensin II receptor blocker and calcium channel blocker on endothelial vasomotor function after everolimus-eluting stent implantation.

What Was Tested

This randomized controlled trial looks at Angiotensin II Type 1 Receptor Blockers.

Olmesartan, an angiotensin II receptor antagonist, ameliorates endothelial dysfunction.

The present study evaluated the protective effect of olmesartan on endothelial function after everolimus-eluting stent (EES) implantation.

Who Took Part

The abstract describes 40 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A total of 40 patients who underwent EES implantation were randomly assigned to the olmesartan group (20 patients with 30 lesions) or the non-olmesartan group (20 patients with 32 lesions).

Endothelial function was estimated by measuring the coronary vasoreactivity in the segments 15mm proximal and distal to EES in response to intracoronary infusion of acetylcholine (Ach; 10(-8) and 10(-7)mol/L) at 9-month follow-up.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Angiotensin II Type 1 Receptor Blockers group and the comparison group should start out alike.

Endothelium-independent vasomotion was assessed after an intracoronary bolus of isosorbide dinitrate.

What Was Measured

The present study evaluated the protective effect of olmesartan on endothelial function after everolimus-eluting stent (EES) implantation.

Topics PubMed links to this paper include Acetylcholine, Angiotensin II Type 1 Receptor Blockers, Calcium Channel Blockers, Drug-Eluting Stents, Endothelium, Vascular, Everolimus and Imidazoles.

The authors tagged it with the keywords Angiotensin II receptor blocker and Endothelial function.

What This Means in Plain Language

The paper is a randomized study of Angiotensin II Type 1 Receptor Blockers in 40 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Journal of cardiology), a journal based in Netherlands.

More context: all human trials.